Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Plus Chemotherapy in Resectable Mucosal Melanoma
NCT07400302Phase 2Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Apr 2026
- Primary completion
- Sep 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in mucosal melanoma (MM), sponsored by The First Hospital of Jilin University. Started Apr 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT07400302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07400302.